Chromadex Corp Company Profile (OTCMKTS:CDXC)

About Chromadex Corp (OTCMKTS:CDXC)

Chromadex Corp logoChromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.

Industry, Sector and Symbol: Capitalization:
  • Market Cap: $206.96 million
  • Outstanding Shares: 46,093,000
Average Prices:
  • 50 Day Moving Avg: $3.53
  • 200 Day Moving Avg: $3.26
  • 52 Week Range: $2.25 - $4.85
P/E:
  • Trailing P/E Ratio: N/A
  • Foreward P/E Ratio: 23.63
  • P/E Growth: 0.0000
Sales & Book Value:
  • Annual Revenue: $20.41 million
  • Price / Sales: 10.14
  • Book Value: $0.56 per share
  • Price / Book: 8.02
Profitability:
  • EBIDTA: ($6,270,000.00)
  • Net Margins: -52.09%
  • Return on Equity: -63.19%
  • Return on Assets: -41.08%
Misc:
  • Average Volume: 341,064 shs.
  • Short Ratio: 11.53
 

Frequently Asked Questions for Chromadex Corp (OTCMKTS:CDXC)

What is Chromadex Corp's stock symbol?

Chromadex Corp trades on the OTCMKTS under the ticker symbol "CDXC."

How were Chromadex Corp's earnings last quarter?

Chromadex Corp (OTCMKTS:CDXC) announced its quarterly earnings results on Thursday, August, 10th. The company reported ($0.05) earnings per share (EPS) for the quarter, missing the Zacks' consensus estimate of $0.04 by $0.09. The business had revenue of $5.31 million for the quarter, compared to analysts' expectations of $11 million. Chromadex Corp had a negative return on equity of 63.19% and a negative net margin of 52.09%. View Chromadex Corp's Earnings History.

When will Chromadex Corp make its next earnings announcement?

Chromadex Corp is scheduled to release their next quarterly earnings announcement on Thursday, November, 9th 2017. View Earnings Estimates for Chromadex Corp.

Where is Chromadex Corp's stock going? Where will Chromadex Corp's stock price be in 2017?

2 equities research analysts have issued 1-year price objectives for Chromadex Corp's shares. Their predictions range from $5.00 to $6.00. On average, they anticipate Chromadex Corp's stock price to reach $5.50 in the next year. View Analyst Ratings for Chromadex Corp.

What are analysts saying about Chromadex Corp stock?

Here are some recent quotes from research analysts about Chromadex Corp stock:

  • 1. According to Zacks Investment Research, "ChromaDex Corporation and its subsidiaries supply phytochemical reference standards and reference materials, related contract services, and products for the dietary supplement, nutraceutical, food and beverage, functional food, pharmaceutical and cosmetic markets. ChromaDex's core business strategy is to use the intellectual property harnessed by its expertise in the area of natural products and in the creation of reference materials to the industry as the basis for providing new and alternative, green, mass marketable products to its customers. The Company's main priority is to create industry-accepted information, and to provide products and services to every layer of the functional food, pharmaceutical, personal care and dietary supplement markets. The company markets and sells its products in the United States and Canada. It offers its products through distributors in Europe, South America, Korea, India, Japan, Australia, New Zealand, China, Indonesia, Malaysia, Singapore, Thailand, and Mexico. " (8/15/2017)
  • 2. HC Wainwright analysts commented, "We note that the company’s revenues came in at $5.3M vs. our original forecast of $8M, while a net loss of $2.7M or $0.07 per share was also recorded vs. our projection for a positive EPS of $0.04. While R&D spending in the quarter was roughly in-line with our estimate at $728K vs. $700K, we note that COGS were slightly worse than our estimate, coming in at 57% vs. our projection of 49%. Given what we see as the current status of ChromaDex’s ingredients business, we have revised our 2017 revenue number to $24.3M, while we now project a net loss per share for 2017 of $0.14 vs. our prior forecast for EPS of $0.16 for the year." (8/11/2017)

Who are some of Chromadex Corp's key competitors?

Who are Chromadex Corp's key executives?

Chromadex Corp's management team includes the folowing people:

  • Stephen Allen, Independent Chairman of the Board
  • Frank L. Jaksch Jr., Chief Executive Officer, Director
  • Thomas C. Varvaro, Chief Financial Officer, Secretary
  • Troy Rhonemus, Chief Operating Officer
  • Kurt A. Gustafson, Director
  • Tony Lau, Director
  • Steven D. Rubin Esq. J.D., Director
  • Wendy Yu, Director
  • Jeffrey Royston Baxter, Independent Director

Who owns Chromadex Corp stock?

Chromadex Corp's stock is owned by a number of of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (2.25%), Tieton Capital Management LLC (1.55%), North Star Investment Management Corp. (0.67%), Granite Investment Partners LLC (0.59%), Goldman Sachs Group Inc. (0.40%) and LMR Partners LLP (0.23%). Company insiders that own Chromadex Corp stock include Frank L Jaksch Jr, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Institutional Ownership Trends for Chromadex Corp.

Who sold Chromadex Corp stock? Who is selling Chromadex Corp stock?

Chromadex Corp's stock was sold by a variety of institutional investors in the last quarter, including Northern Trust Corp, Vanguard Group Inc., Tieton Capital Management LLC, Granite Investment Partners LLC and Arete Wealth Advisors LLC. View Insider Buying and Selling for Chromadex Corp.

Who bought Chromadex Corp stock? Who is buying Chromadex Corp stock?

Chromadex Corp's stock was acquired by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., North Star Investment Management Corp., LMR Partners LLP and Bank of Montreal Can. Company insiders that have bought Chromadex Corp stock in the last two years include Frank L Jaksch Jr, Robert N Fried, Step Holdings Ltd Pioneer, Stephen R Allen and Troy Allen Rhonemus. View Insider Buying and Selling for Chromadex Corp.

How do I buy Chromadex Corp stock?

Shares of Chromadex Corp can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Chromadex Corp's stock price today?

One share of Chromadex Corp stock can currently be purchased for approximately $4.49.


MarketBeat Community Rating for Chromadex Corp (OTCMKTS CDXC)
Community Ranking:  2.8 out of 5 (star star)
Outperform Votes:  64 (Vote Outperform)
Underperform Votes:  52 (Vote Underperform)
Total Votes:  116
MarketBeat's community ratings are surveys of what our community members think about Chromadex Corp and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for Chromadex Corp (OTCMKTS:CDXC) (How are Consensus Ratings Calculated?)
Ratings Breakdown: 2 Buy Ratings
Consensus Rating:Buy (Score: 3.00)
Consensus Price Target: $5.50

Analysts' Ratings History for Chromadex Corp (OTCMKTS:CDXC)
Show:
DateFirmActionRatingPrice TargetDetails
9/11/2017HC WainwrightReiterated RatingBuyView Rating Details
1/3/2017Rodman & RenshawInitiated CoverageBuy$6.00View Rating Details
(Data available from 9/21/2015 forward)

Earnings

Earnings History for Chromadex Corp (OTCMKTS:CDXC)
Earnings by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Earnings History by Quarter for Chromadex Corp (OTCMKTS CDXC)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/8/2017($0.03)N/AView Earnings Details
8/10/2017Q2 2017$0.04($0.05)$11.00 million$5.31 millionViewN/AView Earnings Details
3/16/2017Q4 2016($0.01)($0.06)$5.60 million$5.64 millionViewN/AView Earnings Details
11/10/2016Q3 2016($0.03)$5.01 millionViewListenView Earnings Details
8/11/2016Q216$0.01$6.10 million$8.80 millionViewListenView Earnings Details
5/12/2016Q116$0.01$5.30 million$7.30 millionViewListenView Earnings Details
11/21/2013Q3 13($0.01)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Chromadex Corp (OTCMKTS:CDXC)
Current Year EPS Consensus Estimate: $-0.14 EPS
Next Year EPS Consensus Estimate: $0.19 EPS

Dividends

Dividend History for Chromadex Corp (OTCMKTS:CDXC)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Chromadex Corp (OTCMKTS:CDXC)
Insider Trades by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Institutional Ownership by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Insider Trades by Quarter for Chromadex Corp (OTCMKTS:CDXC)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
8/25/2017Stephen R AllenDirectorBuy2,000$3.31$6,620.00View SEC Filing  
8/18/2017Step Holdings Ltd PioneerMajor ShareholderBuy786,167$2.60$2,044,034.20View SEC Filing  
8/15/2017Robert N FriedInsiderBuy10,000$3.15$31,500.00View SEC Filing  
5/24/2017Step Holdings Ltd PioneerMajor ShareholderBuy2,521,526$2.60$6,555,967.60View SEC Filing  
5/19/2017Stephen R AllenDirectorBuy3,000$3.20$9,600.00View SEC Filing  
3/20/2017Stephen R AllenDirectorBuy2,000$2.81$5,620.00View SEC Filing  
12/12/2016Frank L Jaksch JrCEOBuy2,000$2.42$4,840.00View SEC Filing  
9/1/2016Frank L Jaksch JrCEOBuy1,500$3.32$4,980.00View SEC Filing  
9/1/2016Robert N FriedDirectorBuy15,000$3.39$50,850.00View SEC Filing  
6/20/2016Troy Allen RhonemusCOOBuy7,800$3.47$27,066.00View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Headline Trends for Chromadex Corp (OTCMKTS:CDXC)
Latest Headlines for Chromadex Corp (OTCMKTS:CDXC)
Source:
DateHeadline
nasdaq.com logoChromaDex to Present at the Ladenburg Thalmann 2017 Healthcare Conference - Nasdaq
www.nasdaq.com - September 21 at 10:49 AM
finance.yahoo.com logoChromaDex to Showcase Healthy Aging Ingredients and Phytochemical Reference Standards at SupplySide West 2017
finance.yahoo.com - September 18 at 3:35 PM
americanbankingnews.com logoChromadex Corp (CDXC) & Codexis (CDXS) Critical Analysis
www.americanbankingnews.com - September 17 at 12:32 AM
finance.yahoo.com logoETFs with exposure to Chromadex Corp. : September 14, 2017
finance.yahoo.com - September 14 at 10:48 PM
finance.yahoo.com logoChromadex Corp. :CDXC-US: Earnings Analysis: Q2, 2017 By the Numbers : September 13, 2017
finance.yahoo.com - September 13 at 6:18 PM
americanbankingnews.com logoChromadex Corp (CDXC) Given Buy Rating at HC Wainwright
www.americanbankingnews.com - September 11 at 8:58 PM
americanbankingnews.com logoValuEngine Upgrades Chromadex Corp (CDXC) to "Hold"
www.americanbankingnews.com - September 9 at 11:18 AM
baystreet.ca logoBaystreet.ca - ChromaDex Teams Up with AS Watson to Bring TRU ... - Baystreet.ca
www.baystreet.ca - September 8 at 3:14 AM
nasdaq.com logoChromaDex Partners with Asia's Leading Health and Beauty ... - Nasdaq
www.nasdaq.com - September 8 at 3:14 AM
baystreet.ca logoChromaDex Teams Up with AS Watson to Bring TRU NIAGEN to Asia and Europe
www.baystreet.ca - September 7 at 5:09 PM
finance.yahoo.com logoChromaDex Partners with Asia’s Leading Health and Beauty Retailer, Watsons, for TRU NIAGEN™ Retail Launch
finance.yahoo.com - September 7 at 5:09 PM
nasdaq.com logoLabCorp Completes $1.2-Billion Chiltern Buyout, Boosts CRO
www.nasdaq.com - September 4 at 5:04 PM
zacks.com logoLabCorp's $1.2 Billion Chiltern Buyout Gets FTC Approval
www.zacks.com - August 28 at 4:58 PM
nasdaq.com logoLabCorp to Add ChromaDex's Arm, Inorganic Expansion On Track
www.nasdaq.com - August 24 at 5:09 PM
streetinsider.com logoChromaDex (CDXC) Sells Analytical Testing Business to LabCorp (LH) - StreetInsider.com
www.streetinsider.com - August 23 at 10:22 PM
streetinsider.com logoChromaDex (CDXC) Sells Analytical Testing Business to LabCorp (LH)
www.streetinsider.com - August 23 at 5:21 PM
finance.yahoo.com logoChromaDex Sells its Analytical Testing Business to LabCorp, to Accelerate the Expansion of Nicotinamide Riboside and its Other Patented Ingredient Technologies
finance.yahoo.com - August 23 at 5:20 PM
finance.yahoo.com logoLabCorp purchases analytical testing services business in $8.5 million deal
finance.yahoo.com - August 23 at 5:20 PM
americanbankingnews.com logoStep Holdings Ltd Pioneer Buys 786,167 Shares of Chromadex Corp (CDXC) Stock
www.americanbankingnews.com - August 22 at 10:36 AM
globenewswire.com logoCompany Appoints Tony Lau and Wendy Yu to Board of Directors
globenewswire.com - August 21 at 4:54 PM
nasdaq.com logoChromaDex Announces Closing of Third and Final Tranche of the $25 Million Strategic Investment Led
www.nasdaq.com - August 21 at 4:54 PM
americanbankingnews.com logoRobert N. Fried Acquires 10,000 Shares of Chromadex Corp (CDXC) Stock
www.americanbankingnews.com - August 16 at 9:36 PM
americanbankingnews.com logoZacks Investment Research Lowers Chromadex Corp (CDXC) to Strong Sell
www.americanbankingnews.com - August 15 at 6:08 PM
americanbankingnews.com logoHC Wainwright Reiterates $5.00 Price Target for Chromadex Corp (OTCMKTS:CDXC)
www.americanbankingnews.com - August 13 at 4:38 PM
finance.yahoo.com logoEdited Transcript of CDXC earnings conference call or presentation 10-Aug-17 8:30pm GMT
finance.yahoo.com - August 11 at 5:30 PM
seekingalpha.com logoChromaDex's (CDXC) CEO Frank Jaksch on Q2 2017 Results - Earnings Call Transcript
seekingalpha.com - August 10 at 11:20 PM
americanbankingnews.com logoChromadex Corp (OTCMKTS:CDXC) Posts Earnings Results, Misses Estimates By $0.11 EPS
www.americanbankingnews.com - August 10 at 8:46 PM
finance.yahoo.com logoChromaDex Reports Second Quarter 2017 Financial Results
finance.yahoo.com - August 10 at 6:17 PM
finance.yahoo.com logoChromaDex reports 2Q loss
finance.yahoo.com - August 10 at 6:17 PM
americanbankingnews.com logoChromadex Corp (OTCMKTS:CDXC) Set to Announce Quarterly Earnings on Thursday
www.americanbankingnews.com - August 4 at 3:08 PM
nasdaq.com logoChromaDex® to Report Second Quarter 2017 Financial Results on ... - Nasdaq
www.nasdaq.com - August 4 at 4:39 AM
finance.yahoo.com logoChromaDex® to Report Second Quarter 2017 Financial Results on Thursday, August 10, 2017
finance.yahoo.com - August 3 at 6:36 PM
finance.yahoo.com logoETFs with exposure to Chromadex Corp. : August 1, 2017
finance.yahoo.com - August 1 at 8:36 PM
seekingalpha.com logoChromaDex: New Cash, New Strategy: Will Success Follow? - Seeking Alpha
seekingalpha.com - July 25 at 4:59 PM
americanbankingnews.com logoChromadex Corp (OTCMKTS:CDXC) Stock Rating Lowered by Zacks Investment Research
www.americanbankingnews.com - July 17 at 5:20 PM
finance.yahoo.com logoETFs with exposure to Chromadex Corp. : July 13, 2017
finance.yahoo.com - July 13 at 6:07 PM
nasdaq.com logoChromaDex Sponsors Global Gathering of Scientific Leaders in NAD+ Metabolism and Signaling at the 2
www.nasdaq.com - July 10 at 10:03 PM
finance.yahoo.com logoChromaDex Sponsors Global Gathering of Scientific Leaders in NAD+ Metabolism and Signaling at the 2017 Federation of American Societies for Experimental Biology Conference
finance.yahoo.com - July 10 at 5:01 PM
americanbankingnews.com logoChromadex Corp (CDXC) Downgraded by ValuEngine
www.americanbankingnews.com - July 1 at 10:04 AM
streetinsider.com logoChromaDex (CDXC) Appoints Dr. Rudolph Tanzi, Harvard Neurology Professor to Scientific Advisory Board
www.streetinsider.com - June 27 at 4:27 PM
finance.yahoo.com logoChromaDex Appoints Harvard Medical School Professor of Neurology, Dr. Rudolph Tanzi, to the Scientific Advisory Board
finance.yahoo.com - June 27 at 4:27 PM
finance.yahoo.com logoETFs with exposure to Chromadex Corp. : June 26, 2017
finance.yahoo.com - June 26 at 4:54 PM
finance.yahoo.com logoETFs with exposure to Chromadex Corp. : June 16, 2017
finance.yahoo.com - June 16 at 4:58 PM
finance.yahoo.com logoChromadex Corp. :CDXC-US: Earnings Analysis: Q1, 2017 By the Numbers : June 15, 2017
finance.yahoo.com - June 15 at 5:59 PM
baystreet.ca logoChromadex Joins with Scripps on Breast Cancer Treatment
www.baystreet.ca - June 13 at 12:45 PM
finance.yahoo.com logoChromaDex announces an exclusive worldwide patent license and research agreement with The Scripps Research Institute to identify the potential role of NIAGEN® in treating breast cancer
finance.yahoo.com - June 12 at 5:15 PM
finance.yahoo.com logoChromaDex Names World’s Leading Expert on Nicotinamide Riboside and NAD as Chief Scientific Advisor
finance.yahoo.com - June 5 at 12:20 PM
finance.yahoo.com logoNIAGEN® nicotinamide riboside launches into the functional food space
finance.yahoo.com - May 31 at 10:17 AM
americanbankingnews.com logoChromadex Corp (CDXC) Major Shareholder Step Holdings Ltd Pioneer Acquires 2,521,526 Shares
www.americanbankingnews.com - May 26 at 10:35 AM
finance.yahoo.com logoChromaDex Announces Closing of Second Tranche of the $25 Million Strategic Investment Led by Mr. Li Ka-shing
finance.yahoo.com - May 25 at 5:40 PM

Social

Chart

Chromadex Corp (CDXC) Chart for Thursday, September, 21, 2017

This page was last updated on 9/21/2017 by MarketBeat.com Staff